Abstract 1165
Background
Although several studies report the clinical characteristics of bacteremia by Aeromonas species, there is a lack of studies about the bacteremia course in hematologic malignancies. Our aim was to determine the risk factors for bacteremia-associated mortality by Aeromonas sobria in patients with hematological malignancies.
Methods
We performed a retrospective cohort study, by reviewing 37 medical records of patients treated at the “Instituto Nacional de Enfermedades Neoplasicas-Peru”, in the period of 2000-2017. We considered a bacteremia-related death if it occurred within the first 7 days of A. sobria isolation, or during the acute course of sepsis. Risk factors were assessed by the Multivariate Cox regression analysis at 30 days after the patient’s admission.
Results
The median age was 24y (2-74y), six patients (16.2%) had ≥65y, and 54.1% were male. The most common diagnosis was lymphoid leukemia (51.4%), followed by myeloid leukemia (27%), high-grade lymphoma (18.9%), and multiple myeloma (2.7%); and 37.8% had community-acquired bacteremia. The gastrointestinal system was the most common primary source of infection (62.2%), followed by the osteoarticular system (18.9%). The mortality rate was 27%, and 11 cases (29.7%) presented septic shock. Furthermore, antibiotic use was as follow, meropenem (64.9%), ceftazidime (37.8%), and amikacin (29.7%). Multivariate Cox regression identified age ≥65, shock, and no disease remission as independent risk factors for mortality (Table). Risk factors for Bacteremia-Associated Mortality of Aeromona sobria.Table: 1093P
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
HR | 95% CI | P-value | HR | 95% CI | P-value | |
Age ≥65 | 5.48 | 1.5-19.7 | 0.01 | 8.13 | 1.7-39.4 | 0.009 |
Community-acquire bacteremia | 9.73 | 2.1– 46.1 | 0.004 | - | - | - |
Shock | 13.21 | 2.8–63.0 | 0.001 | 7.06 | 1.5-34.4 | 0.016 |
Non-disease remission | 14.31 | 1.8–113.3 | 0.012 | 10.46 | 1.2-89.8 | 0.024 |
Conclusions
Patients with hematological malignancy infected by A. sobria that either is ≥ 65-years-old does not have a disease remission or develop shock, the risk of dying increases. The physicians can use our results to guide the prognosis of patients infected by this bacteria.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract